ASO Visual Abstract: Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma
本文未提供摘要,请点击“查看全文”查看完整内容。